Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure De

The purpose of this program is to coordinate the acceleration of countermeasure and product advanced research and development by-(A) facilitating collaboration between the Department of Health and Human Services and other Federal agencies, relevant industries, academia, and other persons, with respect
to such advanced research and development; (B) promoting countermeasure and product advanced research and development; (C) facilitating contacts between interested persons and the offices or employees authorized by the Secretary to advise such persons regarding requirements under the Federal Food, Drug, and Cosmetic Act and under section 351 of the Public Health Service Act; and (D) promoting innovation to reduce the time and cost of countermeasure and product advanced research and development.

The Public Health Service Act at 42 U.S.C.

247d-6a defines a qualified countermeasure as "…a drug (as that term is defined by section 321(g)(1) of title 21), biological product (as that term is defined by section 262(i) of this title), or device (as that term is defined by section 321(h) of title 21), that the Secretary determines to be a priority (consistent with sections 182(2) and 184(a) of title 6) to - (i) diagnose, mitigate, prevent, or treat harm from any biological agent (including organisms that cause an infectious disease) or toxin, chemical, radiological, or nuclear agent that may cause a public health emergency affecting national security; or (ii) diagnose, mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, biological product, or device that is used as described in this subparagraph".

Agency - Department of Health and Human Services

The Department of Health and Human Services is the Federal government's principal agency for protecting the health of all Americans and providing essential human services, especially to those who are least able to help themselves.


Relevant Nonprofit Program Categories





Selected Recipients for this Program


RecipientAmount Start DateEnd Date
Plug & Play, Llc $ 200,000   2019-09-012024-08-31
University Enterprise Laboratories, Inc. $ 200,000   2019-09-012024-08-31
University Of Missouri System $ 193,412   2019-09-012024-08-31
Emory University $ 199,872   2019-09-012024-08-30
Life Science Washington Institute $ 299,946   2018-06-012023-05-31
New Orleans Bioinnovation Center, Inc. $ 257,347   2018-06-012023-05-31
Texas Medical Center $ 289,500   2018-06-012023-05-31
Medtech Innovator $ 300,000   2018-06-012023-05-31
First Flight Venture Center, Inc. $ 295,740   2018-06-012023-05-31
University Of Massachusetts $ 299,998   2018-06-012023-05-31



Program Accomplishments

Fiscal Year 2009: No Current Data Available Fiscal Year 2010: It is anticipated that 20 applications will be received and 12 awards will be issued in fiscal year 2010. Fiscal Year 2011: No Current Data Available

Uses and Use Restrictions

Support international in-country advanced development and industrialization of human pandemic influenza vaccine.

Support activities related to the mitigation of the global shortage of influenza vaccines through awards and sub-awards to developing countries with the potential and capacity to manufacture various influenza vaccines.

Basic research (e.g.

scientific or medical experiments) is not allowable.

100% of funds are for discretionary activities.

Eligibility Requirements

Applicant Eligibility

All types of entities are eligible, including highly qualified foreign nationals outside the United States either alone or in collaboration with American participants when such transactions may inure to the benefit of the American people.

Applicants should review the individual funding opportunity announcements issued under this CFDA program.

Beneficiary Eligibility

All individuals including at-risk individuals such as children, pregnant women, elderly, and others at-risk who may be given special priority.

Credentials/Documentation

Applicants should review the individual funding opportunity announcements issued under this CFDA program for any credentials or certifications that must be submitted prior to or simultaneous with submission of an application package. OMB Circular No. A-87 applies to this program.

Aplication and Award Process

Preapplication Coordination

Preapplication coordination is not applicable.

Environmental impact information is not required for this program.